Does it matter if #esophagectomy is performed earlier in the week/closer to #weekend? Does the number & experience of OR/ICU personnel, logistics and infrastructure impact #postoperative outcomes? To find out, read our paper in Journal of Gastrointestinal Cancer Springer Nature #GITwitter #surgery

Look 👀 what arrived in the mail today! Hot off the presses - our new book 📖 Edited by Aslam Ejaz & myself, this book brings together 🌎🌏 experts to cover a broad range of topics on management of #colorectalcancer #metastatic #disease. Be sure to ✔️it out!

GI Subway map for you….American Gastroenterological Association (AGA) ACG Texas Society for Gastroenterology and Endoscopy Austin Gastro GiAlliance ASGE GI Endoscopy #MedTwitter #GITwitter

🚀 LAUNCH trial demonstrates transarterial chemoembolization + lenvatinib improves survival for firstline therapy in patients with advanced #HepatocellularCarcinoma ➡️ fal.cn/3r7Th #JCO #hpbcsm

JCOG1213 (TOPIC NEC), the first randomized phase III trial in advanced neuroendocrine carcinoma of the digestive system, shows no significant difference in overall survival for etoposide+cisplatin versus irinotecan+cisplatin therapy ja.ma/3PD6oKm #GICSM

🔥Global burden of cancer attributable to risk factor🔥 The Lancet doi.org/10.1016/S0140-… 🤔44% of global cancer deaths attributable to risk factors 🧐leading: smoking, alcohol, high BMI 👉Prevention, early diagnosis, effective therapy required ESMO - Eur. Oncology OncoAlert EASL Education

👉Upfront FOLFOXIRI plus Panitumumab does not improve outcome in #CRC now published in Journal of Clinical Oncology doi.org/10.1200/JCO.22… ✅TRIPLETE phs-III, 88% left-sided tumors 👉relative "low" ORR, and more GI toxicity ❌more is not always better... ESMO - Eur. Oncology OncoAlert

Updated 5-year results of the Unicancer PRODIGE 24/CCTG PA6 trial confirmed the significant improvement in all outcomes, including overall survival, with mFOLFIRINOX regimen compared to gemcitabine in adjuvant setting for pts w #pancreaticcancer. ja.ma/3Qd4dgS #GICSM

The LASRE trial established the short-term oncologic safety of using laparoscopic surgery for low rectal cancer. The rate of complete total mesorectal excision was practically identical with laparoscopic surgery (85.3%) vs open surgery (85.8%). ja.ma/3eQamCH #Research

Already thinking about this awesome congress next year: Venice mystery, great science, wonderful friends #PSOGI2023 Peritoneal Surface Oncology Group International ISSPP

Local and systemic therapy in liver cancer: the quest for synergy Matthias Pinter Surgery and Cancer UPO - Università thelancet.com/journals/langa…

Check out this new paper by our Ohio State Wexner Medical Center Surgery Dept. TEAM on guideline adherence to surveillance strategies in patients who underwent resection of #colorectal #cancer ▶️authors.elsevier.com/a/1gcV43QSdFec… #Colon #cancer Zaiba Shafik Dawood Zorays Moazzam, MD Yutaka Endo 遠藤泰 Musaab Munir Laura Alaimo

Viewpoint by David Haggstrom, Signe Braafladt MD, and Paul K.J. Han describes the benefits and challenges of active surveillance as a clinical approach to monitor low-risk cancers with favorable prognoses. ja.ma/3Tevp3p

Systematic review and meta-analysis of the effect of prehabilitation on LOS and functional capacity in pts undergoing resection for CRC. How much is LOS decreased? Read more in this month's #DCRJournal: bit.ly/4cnOfLR @Swexner SoMe4Surgery @ACPGBI Tracy Hull ASCRS_1

From JAMA: Among patients undergoing liver resection for a cancer-related indication, tranexamic acid did not reduce bleeding or blood transfusion but increased perioperative complications. ja.ma/4dza3WA

Welcome to #PancChat! Tonight we are chatting about #Nutrition and #PancreaticCancer.

Laparoscopic versus open right hepatectomy for colorectal liver metastases after portal vein embolization: international multicentre study ⁦BJS⁩ academic.oup.com/bjs/article/11…

Transarterial chemoembolization plus sorafenib for recurrent intermediate-stage hepatocellular carcinoma patients with microvascular invasion improved survival compared with transarterial chemoembolization alone. ja.ma/4fJlyMl

🚨#TOPGEAR ⚙️ results at #ESMO24 RCT: periop chemo w rads 🆚 no rads 👥 574 gastric/GEJ adenocarcinoma ⬆️ pCR with rads ❌ No difference in OS or PFS 🙅🏻‍♀️ That settles it then? 🤨 📝👇🏻

GI Oncology standard regimen doses remain too high for many real world patients. Retrospective and prospective trials demonstrating benefit of reduced doses or dose escalation are accumulating. #meded #gionc #crcsm #pancsm